Skip to main content
. Author manuscript; available in PMC: 2010 Nov 13.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jul 10;33(8):1291–1308. doi: 10.1016/j.pnpbp.2009.06.022

Figure 7.

Figure 7

In two different experiments, the selective CRF-R1 antagonist GSK876008 disrupted potentiated startle to an 8-min CS but did not disrupt potentiated startle to a 3.7-sec presentation of the same stimulus.